

CURRICULUM VITAE

BIOGRAPHICAL

NAME Agostino Consoli, M.D.

HOME ADDRESS Strada Comunale Quagliera Spoltore (Pescara)
I - 66023 - ITALY

BIRTH DATE March 28, 1956
BIRTH PLACE Naples, ITALY
CITIZENSHIP Italian

Mobile PHONE 39 349 3600419

BUSINESS ADDRESS Edificio CAST (ex CeSI-Met) room 351
Campus Università d'Annunzio
Via Luigi Polacchi, 11-13
66100 CHIETI
ITALY

BUSINESS PHONE 39 0871 3552100
E. MAIL <consoli@unich.it>

EDUCATION AND TRAINING

Date attended	Name and Location of Institution	Degree Received
1974 - 1980	University of Chieti - ITALY	Laurea in Medicina Summa cum Laude
1980 - 1985	University of Chieti School of Medicine	Internal Medicine Specialty Degree
1985 - 1986	Mayo Clinic Rochester, MN	Research Fellowship in Endocrinology

ACCADEMIC APPOINTMENTS

YEARS	Name and Location of Institution	TITLE
1983 - 1986	University of Chieti, Italy	Teaching Investigator
1986 - 1991	University of Pittsburgh, Pittsburgh, PA	Research Associate
1991 - 1993	UTHSC, San Antonio, TX	Assistant Professor of Medicine
1993 - 2001	University of Chieti, Italy	Associate Professor of Endocrinology
2001 - present	University of Chieti, Italy	Full Professor of Endocrinology

OTHER APPOINTMENTS AND POSITIONS

2013 - present	University of Chieti, Italy	Director Clinical Research Center
2013 - present	University of Chieti, Italy	Director Endocrinology Fellowship Program
2013 - present	University of Chieti, Italy	Coordinator Translational Medicine PhD Program
2013 - present	University of Chieti, Italy National Health Service – Pescara Agency	Head Endocrinology and Metabolism Clinic
2013 - 2016	University of Chieti, Italy	Director Center of Ageing Sciences and Translational Medicine

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETY

Since 1982	Italian Society of Diabetology	Member
2000 - 2004	Italian Society of Diabetology	Member of National Council Coordinator
2002 - 2004	Italian Society of Diabetology	National Scientific Committee
2018 - 2020	Italian Society of Diabetology	Elected President
Since 2014	Italian Society of Endocrinology	Member
Since 1986	American Diabetes Association	Member
Since 1987	European Association for the Study of Diabetes	Member

COMPETITIVE GRANTS

Year	Title of Grant
1986	Research Grant Award, Juvenile Diabetes Foundation
1986	Feasibility Research Grant Award, American Diabetes Association
1988	Research Grant Award, Juvenile Diabetes Foundation
1991	Research Grant, American Diabetes Association
1998	Research Award. Italian Society of Diabetology
1998	Research Grant, Italian Ministry of Health
1999	Research Grant, Italian Ministry of Health
2000	Research Grant, Italian Ministry of Health
2001	PRIN Research Grant, Italian Ministry of Education Local Coordinator
2004	PRIN Research Grant, Italian Ministry of Education Local Coordinator
2006	PRIN Research Grant, Italian Ministry of Education NATIONAL Coordinator
2009	PRIN Research Grant, Italian Ministry of Education NATIONAL Coordinator
2010	Research Grant, Foundation European Association Study of Diabetes
2012	PRIN Research Grant, Italian Ministry of Education Local Coordinator
2015	PRIN Research Grant, Italian Ministry of Education Local Coordinator
2017	PRIN Research Grant, Italian Ministry of Education NATIONAL Coordinator

PRIVATE RESEARCH SUPPORT

Prof Consoli has received support for Investigator Initiated Studies from the following Companies:

Eli Lilly
Novo Nordisk
Astra Zeneca

SCIENTIFIC PRODUCTION

Orcid # **0000-0002-1885-451X**

Total Citations: **7093**

H Index: **43**

Cited Papers: **159**

MOST SIGNIFICANT 10 PUBLICATIONS

- 1) Consoli A, Kennedy F, Miles J, Gerich J. (1987). Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. *JOURNAL OF CLINICAL INVESTIGATION*, 80 (5) p. 1303-1310. Cited 106 times. IF 2015 12,57
- 2) Consoli A, Nurjhan N, Capani F, Gerich J. (1989). Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. *DIABETES*, 38 (5) p. 550-557. Cited 300 times IF 2015 8,78
- 3) Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, Gerich JE. (1990). Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. *JOURNAL OF CLINICAL INVESTIGATION*, 86 (6) p. 2038-2045. Cited 148 times. IF 2015 12,57.
- 4) Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM, Gerich JE. (1990). Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans. *AMERICAN JOURNAL OF PHYSIOLOGY*, 259 (5) p. E677-E684. Cited 74 times. IF 2015 3,82
- 5) Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, A. Consoli (1996). Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture.. *DIABETOLOGIA*, 39 (12) p. 1425-1431. Cited 50 times. IF 2015 6,21
- 6) Pandolfi A, Cetrullo D, Polishuck R, Alberta Mm, Calafiore A, Pellegrini G, Vitacolonna E, Capani F, A. Consoli (2001). Plasminogen activator inhibitor type 1 is increased in the arterial wall of type 2 diabetic subjects. *ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY*, 21 (8) p. 1378-1382. Cited 44 times. IF 2015 5,97
- 7) Federici Massimo, Pandolfi Assunta, De Filippis Elena Anna, Pellegrini Giuliana, Meneghini Rossella, Lauro Davide, Cardellini Marina, Romano Mario, Sesti Giorgio, Lauro Renato, Consoli Agostino (2004). G972R IRS-1 variant impairs insulin regulation of eNOS in cultured human endothelial cells. *CIRCULATION* 109 (3) p. 399-405. Cited 86 times. IF 2015 17,20
- 8) Andreozzi F, Formoso G, Prudente S, Hribal MI, Pandolfi A, Bellacchio E, Di Silvestre S, Trischitta V, A. Consoli*, Sesti G (2008). TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in human endothelial cells. *ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY*, 28 (7) p. 1355-1360. Cited 41 times. IF 2015 5,97

- 9) Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.
- 10) Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A. Effects of Liraglutide on Weight Loss, Fat Distribution, and β -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. *Diabetes Care*. 2017 Nov;40(11):1556-1564

PUBLICATIONS (Last 10 years)

- 1) Vadini F, Simeone PG, Boccacatonda A, Guagnano MT, Liani R, Tripaldi R, Di Castelnuovo A, Cipollone F, Consoli A, Santilli F. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. *Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study*. *Int J Obes (Lond)*. 2020 Jan 21. doi: 10.1038/s41366-020-0535-5. [Epub ahead of print]
- 2) Mastropasqua L, Perilli R, D'Aloisio R, Toto L, Mastropasqua A, Donato S, Taraborrelli M, Ginestra F, Porta M, Consoli A. Why Miss the Chance? Incidental Findings while Telescreening for Diabetic Retinopathy. *Ophthalmic Epidemiol*. 2020 Jan 20:1-9.
- 3) Sciannameo V, Berchiolla P, Orsi E, Lamacchia O, Morano S, Querci F, Consoli A, Avogaro A, Fadini GP; DARWIN-T2D study. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice. The case of GLP-1 receptor agonists. *Diabetes Obes Metab*. 2020 Jan 14. doi: 10.1111/dom.13962. [Epub ahead of print]
- 4) Santilli F, Zaccardi F, Liani R, Petrucci G, Simeone P, Pitocco D, Tripaldi R, Rizzi A, Formoso G, Pontecorvi A, Angelucci E, Pagliaccia F, Golato M, De Leva F, Vitacolonna E, Rocca B, Consoli A, Patrono C. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. *Diabetes Metab Res Rev*. 2019 Oct 31:e3232. doi: 10.1002/dmrr.3232. [Epub ahead of print]
- 5) Avogaro A, Bonora E, Consoli A, Del Prato S, Genovese S, Giorgino F. Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. *Diab Vasc Dis Res*. 2019 May 2: [Epub ahead of print]
- 6) Formoso G, Baldassarre MPA, Ginestra F, Carlucci MA, Bucci I, Consoli A. Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. *Diabetes Metab Res Rev*. 2019 Jul;35(5):e3154.
- 7) Simeone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano MT, Tartaro A, Bonadonna RC, Federico V, Cipollone F, Consoli A, Santilli F. Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. *Nutrients*. 2018 Dec 2;10(12).
- 8) Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen

- M, Husain M. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. *Diabetes Obes Metab.* 2019 Mar;21(3):499-508.
- 9) Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev.* 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4.
 - 10) Volpe M, Tocci G, Accettura D, Battistoni A, Bellone S, Bellotti P, Bertolotti M, Borghi C, Casasco M, Consoli A, Coppini R, Corsini A, Costanzo G, Desideri G, Ferri C, Galanti G, Giada F, Icardi G, Lombardi N, Modena MG, Modesti PA, Monti G, Mugelli A, Orsi A, Parati G, Pedretti RF, Perseghin G, Pirro M, Ricotti R, Rizzoni D, Rotella C, Rubattu S, Salvetti G, Sarto P, Tassinari F, Trimarco B, de Kreutzenberg SV, Volpe R. [Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018]. *G Ital Cardiol (Rome).* 2018 Feb;19(2 Suppl 1):1S-95S.
 - 11) Fadini G.P., Bottigliengo D., D'Angelo F, Cavalot F, Bossi A.C., Zatti G., Baldi I., Avogaro A., Consoli A., Formoso G., Grossi, G., Pucci, A, Sesti, G. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. *Diabetes Therapy* 2018, 9:1477.
 - 12) Formoso G., Ginestra F., Di Dalmazi G., Consoli, A. Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. *Acta Diabetologica* 2018, 55:759
 - 13) Fadini, G.P., Zatti, G., Baldi, I., Bottigliengo D., Consoli A., Giaccari A., Sesti, G., Avogaro, A., for the DARWIN-T2D network. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. *Diabetes, Obesity and Metabolism* 2018, 20:1781
 - 14) Baldassarre, M.P.A., Andersen, A., Consoli, A., Knop, F.K., Vilsbøll, T. Cardiovascular biomarkers in clinical studies of type 2 diabetes. *Diabetes, Obesity and Metabolism* 2018, 20:1350
 - 15) Consoli A, Formoso G, Baldassarre MPA, Febo F A Comparative Safety Review between GLP-1 Receptor Agonists and SGLT2 Inhibitors for Diabetes Treatment. *Expert Opin Drug Saf.* 2018 Jan 15. [Epub ahead of print]
 - 16) Sesti G, Antonelli Incalzi R, Bonora E, Consoli A, Giaccari A, Maggi S, Paolisso G, Purrello F, Vendemiale G, Ferrara N. Management of diabetes in older adults. *Nutr Metab Cardiovasc Dis.* 2017 Dec 7. [Epub ahead of print].
 - 17) Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWIN-T2D Network. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evldeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity *Nutr Metab Cardiovasc Dis.* 2017 Dec;27(12):1089-1097.

- 18) Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol.* 2017 Nov;5(11):887-897.
- 19) Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A. Effects of Liraglutide on Weight Loss, Fat Distribution, and β -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. *Diabetes Care.* 2017 Nov;40(11):1556-1564
- 20) Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, Consoli A, Formoso G. Liraglutide mitigates TNF- α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. *Diabetes Metab Res Rev.* 2017 Nov;33(8)
- 21) Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.
- 22) Bonadonna, R.C., Borghi, C., Consoli, A., Volpe, M. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere(2016) *Nutrition, Metabolism and Cardiovascular Diseases*, 26 (9), pp. 759-766.
- 23) Consoli, A., Formoso, G. Potential side effects to GLP-1 agonists: Understanding their safety and tolerability. (2015) *Expert Opinion on Drug Safety*, 14 (2), pp. 207-218.
- 24) Ampudia-Blasco, F.J., Benhamou, P.Y., Charpentier, G., Consoli, A., Diamant, M., Gallwitz, B., Khunti, K., Mathieu, C., Ridderstråle, M., Seufert, J., Tack, C., Vilsbøll, T., Phan, T.-M., Stoevelaar, H. A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes(2015) *Diabetes Technology and Therapeutics*, 17 (3), pp. 194-202.
- 25) Lattanzio, S., Santilli, F., Liani, R., Vazzana, N., Ueland, T., Di Fulvio, P., Formoso, G., Consoli, A., Aukrust, P., Davì, G. Circulating dickkopf-1 in diabetes mellitus: Association with platelet activation and effects of improved metabolic control and low-dose aspirin. (2014) *Journal of the American Heart Association*, 3 (4), 12
- 26) Ambra, R., Manca, S., Palumbo, M.C., Leoni, G., Natarelli, L., De Marco, A., Consoli, A., Pandolfi, A., Virgili, F. Transcriptome analysis of human primary endothelial cells (HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate sites for an epigenetic modulation of specific gene expression (2014) *Genomics*, 103 (5-6), pp. 337-348.
- 27) Di Fulvio, P., Pandolfi, A., Formoso, G., Di Silvestre, S., Di Tomo, P., Giardinelli, A., De Marco, A., Di Pietro, N., Taraborrelli, M., Sancilio, S., Di Pietro, R., Piantelli, M., Consoli, A. Features of endothelial dysfunction in umbilical cord vessels of women with gestational diabetes (2014) *Nutrition, Metabolism and Cardiovascular Diseases*, 24 (12), pp. 1337-1345.

- 28) Santovito, D., De Nardis, V., Marcantonio, P., Mandolini, C., Paganelli, C., Vitale, E., Buttitta, F., Bucci, M., Mezzetti, A., Consoli, A., Cipollone, F. Plasma exosome MicroRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control (2014) *Journal of Clinical Endocrinology and Metabolism*, 99 (9), pp. E1681-E1685.
- 29) Consoli, A., Formoso, G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? (2013) *Diabetes, Obesity and Metabolism*, 15 (11), pp. 967-977.
- 30) Bonomini, M., Di Liberato, L., Del Rosso, G., Stingone, A., Marinangeli, G., Consoli, A., Bertoli, S., De Vecchi, A., Bosi, E., Russo, R., Corciulo, R., Gesualdo, L., Giorgino, F., Cerasoli, P., Di Castelnuovo, A., Monaco, M.P., Shockley, T., Rossi, C., Arduini, A. Effect of an l-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: A 4-Month, prospective, multicenter randomized trial (2013) *American Journal of Kidney Diseases*, 62 (5), pp. 929-938.
- 31) Bomba, M., Ciavardelli, D., Silvestri, E., Canzoniero, L.M.T., Lattanzio, R., Chiappini, P., Piantelli, M., Di Ilio, C., Consoli, A., Sensi, S.L. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals (2013) *Cell Death and Disease*, 4 (5), art. no. e612,
- 32) Bacci, S., Prudente, S., Copetti, M., Spoto, B., Rizza, S., Baratta, R., Di Pietro, N., Morini, E., Di Paola, R., Testa, A., Mallamaci, F., Tripepi, G., Zhang, Y.-Y., Mercuri, L., Di Silvestre, S., Lauro, R., Malatino, L., Consoli, A., Pellegrini, F., Pandolfi, A., Frittitta, L., Zoccali, C., Federici, M., Doria, A., Trischitta, V. Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance (2013) *Atherosclerosis*, 226 (1), pp. 140-145.
- 33) Formoso, G., Taraborrelli, M., Guagnano, M.T., D'Adamo, M., Di Pietro, N., Tartaro, A., Consoli, A. Magnetic Resonance Imaging Determined Visceral Fat Reduction Associates with Enhanced IL-10 Plasma Levels in Calorie Restricted Obese Subjects (2012) *PLoS ONE*, 7 (12),
- 34) Bolli, G.B., Consoli, A., Giaccari, A. Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGINAL study results (2012) *Nutrition, Metabolism and Cardiovascular Diseases*, 22 (12), pp. 1007-1012.
- 35) Prudente, S., Sesti, G., Pandolfi, A., Andreozzi, F., Consoli, A., Trischitta, V. The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases (2012) *Endocrine Reviews*, 33 (4), pp. 526-546.
- 36) Andreozzi, F., Presta, I., Mannino, G.C., Scarpelli, D., Di Silvestre, S., Di Pietro, N., Succurro, E., Sciacqua, A., Pandolfi, A., Consoli, A., Hribal, M.L., Perticone, F., Sesti, G. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity (2012) *PLoS ONE*, 7 (4)
- 37) Bianchi, C., Miccoli, R., Bonadonna, R.C., Giorgino, F., Frontoni, S., Faloia, E., Marchesini, G., Dolci, M.A., Alviggi, L., Gnasso, A., Consoli, A., Cavalot, F., Cavallo, M.G., Leonetti, F., Giaccari, A., Del Prato, S. Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study (2011) *Nutrition, Metabolism and Cardiovascular Diseases*, 21 (9), pp. 699-705.
- 38) Franciosi, M., Lucisano, G., Pellegrini, F., Cantarello, A., Consoli, A., Cucco, L., Ghidelli, R., Sartore, G., Sciangula, L., Nicolucci, A. ROSES: Role of self-monitoring of blood glucose and intensive education in patients with Type2 diabetes not receiving insulin. A pilot randomized clinical trial (2011) *Diabetic Medicine*, 28 (7), pp. 789-796.
- 39) Consoli, A. New therapeutic algorithm of Type 2 diabetes: Lights and shadows (2011) *Journal of Endocrinological Investigation*, 34 (1), pp. 65-68.

- 40) Formoso, G., Di Tomo, P., Andreozzi, F., Succurro, E., Di Silvestre, S., Prudente, S., Perticone, F., Trischitta, V., Sesti, G., Pandolfi, A., Consoli, A. The TRIB3 R84 variant is associated with increased carotid intima-media thickness in vivo and with enhanced MAPK signalling in human endothelial cells (2011) *Cardiovascular Research*, 89 (1), pp. 184-192.

- 41) Santilli, F., Formoso, G., Sbraccia, P., Averna, M., Miccoli, R., Di Fulvio, P., Ganci, A., Pulizzi, N., Lattanzio, S., Ciabattini, G., CONSOLI, A., Lauro, R., Patrono, C., Davì, G. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus (2010) *Journal of Thrombosis and Haemostasis*, 8 (4), pp. 828-837.